

REFERENCES

- Accelrys Software Inc., Discovery Studio Modeling Environment, Release 3.1, Accelrys Software Inc., San Diego, 2011.
- Acoca, S., Cui, Q., Shore, G.C. and Purisima, E.O., Molecular dynamics study of small molecule inhibitors of the Bcl-2 family, *Proteins*, 79, 2624–2636, 2011.
- Adams, J.M. and Cory, S., Life-or-death decisions by the Bcl-2 protein family, *Trends Biochem. Sci.*, 26, 61-66, 2001.
- Ajay and Murcko, M.A., Computational methods to predict binding free energy in ligand-receptor complexes, *J. Med. Chem.*, 38, 4953–4967, 1995.
- Ali, M.M., Roe, S.M., Vaughan, C.K., Meyer, P., Panaretou, B., Piper, P.W., Prodromou, C. and Pearl, L.H., Crystal structure of an Hsp90–nucleotide-p23/Sba1 closed chaperone complex, *Nature*, 440, 1013–1017, 2006.
- Allen, J.G., Bourbeau, M.P., Wohlhieter, G.E., Bartberger, M.D., Michelsen, K., Hungate, R., Gadwood, R.C., Gaston, R.D., Evans, B., Mann, L.W., Matison, M.E., Schneider, S., Huang, X., Yu, D., Andrews, P.S., Reichelt, A., Long, A.M., Yakowec, P., Allen, J.G., Bourbeau, M.P., Wohlhieter, G.E., Bartberger, M.D., Michelsen, K., Hungate, R., Gadwood, R.C., Gaston, R.D., Evans, B., Mann, L.W., Matison, M.E., Schneider, S., Huang, X., Yu, D., Andrews, P.S., Reichelt, A., Long, A.M., Yakowec, P., Yang, E.Y. and Lee, T.A., Oliner, J.D., Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse

- double minute 2-tumor protein 53 protein–protein interaction, *J. Med. Chem.*, 52, 7044–7053, 2009.
- Amadei, A., Linssen, A.B. and Berendsen, H.J., Essential dynamics of proteins, *Prot.*, 17, 412–425, 1993.
- An, W.W., Wang, M.W., Tashiro, S., et al., Norcantharidin induces human melanoma A375-S2 cell apoptosis through mitochondrial and caspase pathways. *J. Korean Med. Sci.*, 19, 560, 2004.
- Antignani, A. and Youle, R.J., How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?, *Curr. Opin. Cell Biol.*, 18, 685-689, 2006.
- Aplin, A.E., Howe, A., Alahari, S.K. and Juliano, R.L., Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins, *Pharmacol. Rev.*, 50, 197–263, 1998.
- Bautista, A.D., Appelbaum, J.S., Craig, C.J., Michel, J. and Schepartz, A., Bridged $\alpha 3$ -Peptide Inhibitors of p53–hDM2 complexation: correlation between affinity and cell permeability, *J. Am. Chem. Soc.*, 132, 2904–2906, 2010.
- Baxter, C.A., Murray, C.W., Clark, D.E., Westhead, D.R. and Eldridge, M.D., Flexible docking using tabu search and an empirical estimate of binding affinity, *Proteins: Structure, Function, and Bioinformatics*, 33, 367–382, 1998.
- Berendsen, H.J.C., Van der Spoel, D., Van Drunen, R., GROMACS - A Message-passing parallel molecular dynamics implementation, *Phys. Commun.* 91, 43–56, 1995.

- Bergeron, M., Gidday, J.M., Yu, S.A., Semenza, Y., Ferriero, G.L., Sharp and F.R., D.M., Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain, *Ann. Neuro.*, 48, 285–296, 2000.
- Bischoff, S.C., Quercetin: potentials in the prevention and therapy of disease, *Cur. Opin. Clin. Nutr. Metab. Care*, 11, 733–740, 2008.
- Blumenthal, M. and Busse, W.R. (Eds.), *The Complete German Commission E. Monographs: Therapeutic Guide to Herbal Medicines*. American Botanical Council, Austin, Tex. Hahn, G., Lehmann, H.D., Kurten, N., Uebel, H. and Vogel, G., 1968. Recent flavonoid research, *Arzneim. Forsch.* 18, 698, 1998.
- Bodnar, A.G., Ouellete, M., Frolkis, M., Holt, S.E., Chiu, C., Morin, G.B., Harley, C.B., Shay, J.W., Lichtsteiner, S. and Wright, W.E., Extension of life-span by introduction of telomerase into normal human cells, *Science*, 279, 349–352, 1998.
- Boström, J., Norrby, P.O. and Liljefors, T.J., Conformational energy penalties of protein-bound ligands, *J. Computer-Aided Mol. Des.*, 12, 383–396, 1998.
- Bottger, A., Bottger, V., Garcia-Echeverria, C., Chene, P., Hochkeppel, H.K., Sampson, W., Ang, K., Howard, S.F., Picksley, S.M. and Lane, D.P., Molecular characterization of the hdm2-p53 interaction. *J. Mol. Biol.*, 269: 744 – 756, 1997.
- Bottger, V., Bottger, A., Howard, S.F., Picksley, S.M., Chene, P., Garcia-Echeverria, C., Hochkeppel, H.K. and Lane, D.P., Identification of novel MDM2 binding peptides by phage display, *Oncogene*, 13, 2141–2147, 1996.
- Bowler, P.J., *Evolution: The History of an Idea*, University of California Press, 2003.

- Brooks, B.R., Brooks, C.L., Mackerell, A.D. et al., CHARMM: the biomolecular simulation program, *J. Comput. Chem.*, 30, 1545–1614, 2009.
- Caia, Y., Luob, Q., Sunc, M. and Corke, H., Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer, *Life Sci.*, 74, 2157–2184, 2004.
- Calderwood, S.K., Khaleque, M.A., Sawyer, D.B. and Ciocca, D.R., Heat shock proteins in cancer: chaperones of tumorigenesis, *Trends Biochem. Sci.*, 31, 164–172, 2006.
- Caltagirone, S., Rossi, C., Poggi, A., Ranelletti, F.O., Natali, P.G., Brunetti, M., Aiello, F.B. and Piantelli, M., Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential, *Internat. J. Can.*, 87, 595–600, 2000.
- Cantley, L.C. and Neel, B.G., New insights into tumor sup plaspression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway, *Proc. Natl. Acad. Sci. USA*, 96, 4240–4245, 1999.
- Case, D.A., Cheatham, T.E., Darden, T. et al., The Amber biomolecular simulation programs, *Comput. Chem.*, 26, 1668–1688, 2005.
- Chambers, A.F. and Matrisian, L.M., Changing views of the role of matrix metalloproteinases in metastasis, *J. Natl. Cancer Inst.*, 89, 1260–1270, 1997.
- Chen, C., Zhou, J. and Ji, C., Quercetin: a potential drug to reverse multidrug Resistance, *Life Sci.*, 87, 333–338, 2010.
- Chen, J., Marechal, V. and Levine, A.J., Mapping of the p53 and mdm-2 interaction domains. *Mol. Cell. Biol.*, 13, 4107–4114, 1993.

- Chen, J., Wang, J., Xu, B., Zhu, W. and Li, G., Insight into mechanism of small molecule inhibitors of the MDM2-p53 interaction: molecular dynamics simulation and free energy analysis, *J. Mol. Graph. Mod.*, 30, 46–53, 2011.
- Chen, Y., Xiao, P., Ou-Yang, D.S., Fan, L., Guo, D. and Wang, Y.N., et al., Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, Nacetyltransferase and xanthine oxidase activity in healthy volunteers, *Clin. Exp. Pharmacol. Physiol.*, 36, 828–833, 2009.
- Chene, P., Inhibiting the p53–MDM2 interaction: an important target for cancer therapy, *Nat. Rev. Cancer.*, 2, 102–109, 2003.
- Cho, S.S., Weinkam, P. and Wolynes, P.G., Origins of barriers and barrierless folding in BBL, *Proc. Nat. Acad. Sci.*, 105, 118-123, 2009.
- Cochran, A.G., *Chem. Biol.*, 7, R85, 2000 (b) Manley, P.W., Furet, P., In *Anticancer Agents: Frontiers in Cancer Chemotherapy*; Ojima, I., Vite, G., Altmann, K., Eds. ACS Symposium Series 796; American Chemical Society: Washington, DC, 282, 2001.
- Colombo, G., Morra, G., Meli, M. and Verkhivker, G., Understanding ligand-based modulation of the Hsp9 molecular chaperone dynamics at atomic resolution, *Proc. Nat. Acad. Sci. USA*, 105, 7976–7981, 2010.
- Coussens, L.M. and Werb, Z., Matrix metalloproteinases and the development of cancer, *Chem. Biol.*, 3, 895–904, 1996.

- Dastidar, S.G., Lane, D.P. and Verma, C.S., modulation of p53 binding to MDM2: computational studies reveal important role of Tyr 100, BMC bioinformatics Proceedings, 2009.
- Day, C.L., Chen, L., Richardson, S.J., Harrison, P.J., Huang, D.C.S., Hinds, M.G., Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands, J. Biol. Chem., 280, 4738–4744, 2005.
- De Vries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N. and Williams, L.T., The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor, Science, 255, 989-991, 1992.
- DeLano , W.L., The PyMOL Molecular Graphics System, DeLano Scientific LLC, San Carlos, CA, USA (<http://www.pymol.org>).
- Dhanasekaran, M., Holcomb, L.A., Hitt, A.R., Tharakan, B., Porter, J.W., Young, K.A. and Manyam, B.V., Centella asiatica extract selectively decreases amyloid beta levels in hippocampus of Alzheimer’s disease animal model, Phytother. Res., 23, 14–19, 2009.
- Ding, J., Zhang, Z., Roberts, G.J., Falcone, M., Miao, Y., Shao, Y., Zhang, X.C., Andrews, D.W. and Lin, J., Bcl-2 and Bax Interact via the BH1–3 Groove-BH3 Motif Interface and a Novel Interface Involving the BH4 Motif, J. Biol. Chem., 285, 28749–28763, 2010.
- Ding, T., Tian, S., Zhang, Z., Gu, D., Chen, Y., Shi, Y. and Sun, Z., Determination of active components in silymarin by RP-LC and LC/MS, J. Pharm. Biomed. Anal. 26, 155–161, 2001.

- Discovery Studio Modeling Environment, Release 3.1, Accelrys Software Inc., San Diego, 2011.
- Dlugosz, P.J., Billen, L.P., Annis, M.G., Zhu, W., Zhang, Z., Lin, J., Leber, B. and Andrews, D.W., Bcl-2 changes conformation to inhibit Bax oligomerization, *EMBO J.*, 25, 2287–2296, 2006.
- Donnelly, A. and Blagg, B.S., Novobiocin and additional inhibitors of the Hsp90 Cterminal nucleotide-binding pocket, *Cur. Med. Chem.*, 15, 2702–2717, 2008.
- Downward, J., Mechanisms and consequences of activation of protein kinase B/Akt, *Curr. Opin. Cell Biol.*, 10, 262–267, 1998.
- Duraj, J., Zazrivcova, K., Bodo, J., Sulikova, M. and Sedlak, J., Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants, *Neoplasma*, 52, 273–279, 2005.
- Dvorak, H.F., Brown, L.F., Detmar, M. and Dvorak, A.M., Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis, *Am. J. Pathol.*, 146, 1029-1039, 1995.
- Espinoza-Fonseca, L.M. and García-Machorro, J., Aromatic–aromatic interactions in the formation of the MDM2-p53 complex, *Biochem. Biophys. Res. Comm.* 370, 547–551, 2008.
- Evan, G. and Littlewood, T., A matter of life and cell death, *Science*, 281, 1317–1322, 1998.
- Fasan, R., Dias, R.L.A., Moehle, K., Zerbe, O., Vrijbloed, J.W., Obrecht, D. and Robinson, J.A., Using a β -hairpin to mimic alpha-helix- Novel cyclic

- peptidomimetic inhibitors of the p53–HDM2 protein–protein interaction, *Angew. Chem. Int. Ed.*, 43, 2109–2112, 2004.
- Fedi, P., Tronick, S.R. and Aaronson, S.A., Growth factors. In *Cancer Medicine*, Holland, (Baltimore, MD: Williams and Wilkins), 1997:41–64.
- Fedi, P., Tronick, S.R. and Aaronson, S.A., Growth factors. In *Can. Med.*, 41–64, 1997.
- Ferrara, N., Gerber, H.P. and LeCouter, J., The biology of VEGF and its receptors, *Nat. Med.*, 9, 669-76, 2003.
- Ferrarini, M., Heltai, S., Zocchi, M.R. and Rugarli, C., Unusual expression and localization of heat-shock proteins in human tumor-cells, *Int. J. Can.*, 51, 613–619, 1992.
- Flaig, T.W., Glodé, L.M., Gustafson, D., van Bokhoven, A., Tao, Y., Wilson, S., Su, L.J., Li, Y., Harrison, G., Agarwal, R., Crawford, E.D., Lucia, M.S. and Pollak, M., A study of high-dose oral silybinin-phytosome followed by prostatectomy in patients with localized prostate cancer, *Prostate*, 70, 848–855, 2010.
- Flaig, T.W., Gustafson, D.L., Su, L.J., Zirrolli, J.A., Crighton, F., Harrison, G.S., Pierson, A.S., Agarwal, R. and Glodé, L.M., A phase I and pharmacokinetic study of silybininphytosome in prostate cancer patients, *Invest. New Drugs*, 25, 139–146, 2007.
- Folkman, J. and Shing, Y., Angiogenesis, *J. Biol. Chem.*, 267, 10931-10934, 1992.
- Folkman, J., What is the evidence that tumors are angiogenesis dependent?, *J. Natl. Cancer Inst.*, 82, 4-6, 1990.

- Formica, J.V. and Regelsont, W., Review of the biology of quercetin and related bioflavonoids, *Food Chem. Toxic.*, 33, 1061–1080, 1995.
- Freedman, D.A., Epstein, C.B., Roth, J.C. and Levine, A.J., A genetic approach to mapping the p53 binding site in the MDM2 protein. *Mol. Med.*,3, 248–259, 1997.
- Fynan, T.M. and Reiss, M., Resistance to inhibition of cell growth by transforming growth factor- β and its role in oncogenesis, *Crit. Rev. Oncog.* 4, 493–540, 1993.
- Ghosh, A. and Vishveshwara, S., A study of communication pathways in methionyl-tRNA synthetase by molecular dynamics simulations and structure network analysis, *Proc. Nat. Acad. Sci.*, 104, 15711-15716, 2007.
- Graham, J.G., Quinn, M.L., Fabricant, D.S. and Farnsworth, N.R., Plants used against cancer—an extension of the work of Jonathan Hartwell, *J. Ethnopharma.*, 73,347–377, 2000.
- Grasberger, B.L., Lu, T., Schubert, C., Parks, D.J., Carver, T.E., Koblisch, H.K., Cummings, M.D., LaFrance, L.V., Milkiewicz, K.L., Calvo, R.R., Maguire, D., Lattanze, J., Franks, C.F., Zhao, S., Ramachandren, K., Bylebyl, G.R., Zhang, M., Manthey, C.L., Petrella, E.C., Pantoliano, M.W., Deckman, I.C., Spurlino, J.C., Maroney, A.C., Tomczuk, B.E., Molloy, C.J. and Bone, R.F., Discovery and cocrystal structure of benzodiazepinedione MDM2 antagonists that activate p53 in cells, *J. Med. Chem.*, 48, 909–912, 2005.
- Green, D.R. and Kroemer, G., The pathophysiology of mitochondrial cell death, *Science*, 305, 626-629, 2004.

- Grover, A., Shandilya, A., Agrawal, V., Pratik, P., Bhasme, D., Bisaria, V.S. and Sundar, D., Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors, *Biochem. Biophys. Res. Comm.*, 404, 498–503, 2011.
- Grover, A., Shandilya, A., Agrawal, V., Pratik, P., Bhasme, D., Bisaria, V.S. and Sundar, D., Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A, *BMC Bioinfo.* 12, Suppl. 1, S30, 2011.
- Grover, A., Shandilya, A., Bisaria, V.S. and Sundar, D., Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes, *BMC Gen.*, 11, Suppl. 4, S15, 2010.
- Gschwend, D.A., Good, A.C. and Kuntz, I.D., Molecular docking towards drug discovery, *J. Mol. Rec.*, 9, 175–186, 1996.
- Gumbart, J., Trabuco, L.G., Schreiner, E., Villa, E. and Schulten, K., Regulation of the protein-conducting channel by a bound ribosome, *Structure*, 17, 1453-1464, 2009.
- Halperin, I., Ma, B., Wolfson, H. and Nussinov, R., Principles of docking: An overview of search algorithms and a guide to scoring functions, *Proteins*, 47, 409–443, 2002.
- Hanahan, D. and Folkman, J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, *Cell*, 86, 353–364, 1996.
- Harris, C.C., p53 tumor suppressor gene: from the basic research laboratory to the clinic—an abridged historical perspective, *Carcinogenesis*, 17, 1187–1198, 1996.

- Haupt, Y., Maya, R., Kazaz, A. and Oren, M., MDM2 promotes the rapid degradation of p53. *Nature*, 387, 296–299, 1997.
- Hertog, M.G., Feskens, E.J., Hollman, P.C., Katan, M.B. and Kromhout, D., Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study, *Lancet*, 342, 1007–1011, 1993.
- Hertog, M.G., Hollman, P.C., Katan, M.B. and Kromhout, D., Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands, *Nutrition and Cancer*, 20, 21–29, 1993.
- Hess, B., Kutzner, C., van der Spoel, D. and Lindahl, E., GROMACS 4, Algorithms for highly efficient, load-balanced, and scalable molecular simulation, *J. Chem. Theory Comput.*, 4, 435-447, 2008.
- Hicklin, D.J. and Ellis, L.M., Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, *J. Clin. Oncol.*, 23, 1011-1027, 2005.
- Hsieh, T.C. and Wu, J.M., Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin, *Anticancer Res.*, 29, 4025–4032, 2009.
- Hunter, T. and Poon, R.Y.C., Cdc37: a protein kinase chaperone, *Trends Cell Biol.*, 7, 157–161, 1997.
- Igney, F.H. and Krammer, P.H., Death and anti-death: tumour resistance to apoptosis, *Nat. Rev.* 2, 277-288, 2002.
- Isaacs, J.S., Xu, W.P. and Neckers, L., Heat shock protein 90 as a molecular target for cancer therapeutics, *Cancer Cell*, 3, 213–217, 2003.

- Janin, Y.L., Heat shock protein 90 inhibitors, a text book example of medicinal chemistry, *J. Med. Chem.*, 48, 7503–7512, 2005.
- Jiang, Y., Bernard, D., Yu, Y., Xie, Y., Zhang, T., Li, Y., Burnett, J.P., Fu, X., Wang, S. and Sun, D., Split renilla luciferase protein fragment-assisted complementation (SRLPFAC) to characterize Hsp90–cdc37 complex and identify critical residues in protein/protein interactions, *J. Biol. Chem.*, 285, 21023–21036, 2010.
- Jin, F., Nieman, D.C., Shanely, R.A., Knab, A.M., Austin, M.D. and Sha, W., The variable plasma quercetin response to 12-week quercetin supplementation in humans, *Eur. J. Clin. Nutr.*, 64, 692–697, 2010.
- Jo, S., Kim, T., Iyer, V.G. and Im, W., CHARMM-GUI: a web-based graphical user interface for CHARMM, *J. Comput. Chem.*, 29, 1859-1865, 2008.
- Jogalekar, A.S., Reiling, S., Vaz, R.J., Identification of optimum computational protocols for modeling the aryl hydrocarbon receptor (AHR) and its interaction with ligands. *Bioorg. Med. Chem. Lett.*, 20, 6616–6619, 2010.
- Johnson, J.P., Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease, *Cancer Metastasis Rev.*, 10, 11–22, 1991.
- Jyoti, A. and Sharma, D., Neuroprotective role of Bacopa monniera extract against aluminium-induced oxidative stress in the hippocampus of rat brain, *Neurotoxicology*, 27, 451–457, 2006.
- Kamal, A., Boehm, M.F. and Burrows, F.J., Therapeutic and diagnostic implications of Hsp90 activation, *Trends Mol. Med.*, 10, 283–290, 2004.

- Kang, J.W., Kim, J.H., Song, K., Kim, S.H., Yoon, J.H. and Kim, K.S., Kaempferol and quercetin, components of Ginkgo biloba extract (EGb761), induce caspase-3-dependent apoptosis in oral cavity cancer cells, *Phytother. Res.*, 24, S77–S82, 2010.
- Khan, M.W., Alam, M., A survey of application: Genomics and genetic programming, A new front. *Gen.*, 100, 65–71, 2012.
- Kiehlmann, E. and Edmond, P.M., Isomerisation of dihydroquercetin, *J. Nat. Prod.* 58, 450–455, 1995.
- Kim, H., Rafiuddin-Shah, M., Tu, H.C., Jeffers, J.R., Zambetti, G.P., Hsieh, J.J.D. and Cheng, E.H.Y., Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies, *Nat. Cell Biol.*, 8, 1348-1358, 2006.
- Kim, N.C., Graf, T.N., Sparacino, C.M., Wani, M.C. and Wall, M.E., Complete isolation and characterization of silybins and isosilybins from milk thistle (*Silybum marianum*), *Org. Biomol. Chem.*, 1, 1684–1689, 2003.
- Kitchen, D.B., Decornez, H., Furr, J.R. and Bajorath, J., Docking and scoring in virtual screening for drug discovery: methods and applications, *Nat. Rev. Drug Dis.*, 3, 935–949, 2004.
- Klagsbrun, M. and D'Amore, P.A., Regulators of angiogenesis, *Annu. Rev. Physiol.*, 53, 217-239, 1991.
- Koblish, H.K., Zhao, S., Franks, C.F., Donatelli, R.R., Tominovich, R.M., LaFrance, L.V.,
- Kolch, W., Ras/Raf signalling and emerging pharmacotherapeutic targets, *Exp. Opin. Pharmacol. Ther.*, 3, 709–718, 2002.

- Kressler, J., Millard-Stafford, M. and Warren, G.L., Quercetin and endurance exercise capacity: a systematic review and meta-analysis, *Med. Sci. Sports and Exer.* 43, 2396–2404, 2011.
- Kritzer, J.A., Lear, J.D., Hodsdon, M.E. and Schepartz, A., Helical α -peptide inhibitors of the p53–hDM2 interaction, *J. Am. Chem. Soc.*, 126, 9468–9469, 2004.
- Ku, B., Liang, C., Jung, J.U. and Oh, B., Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX, *Cell Res.*, 21, 627-641, 2011.
- Kubbutat, M.H. and Vousden, K.H., Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability, *Mol. Cell. Biol.*, 17, 460–468, 1997.
- Kubbutat, M.H., Jones, S.N. and Vousden, K.H., Regulation of p53 stability by MDM2. *Nature*, 387,299–303, 1997.
- Kumar, P.B.N., Gupta, A.P. and Kaul, B.S.K., A rapid RP-HPTLC densitometry method for simultaneous determination of major flavonoids in important medicinal plants, *J. Sep. Sci.*, 30, 2092–2096, 2007.
- Kumar, V., Potential medicinal plants for CNS disorders: an overview, *Phytother. Res.*, 20, 1023–1035, 2006.
- Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A.J. and Pavletich, N.P., Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain, *Science*, 274, 948–953, 1996.
- Kuttner, Y.Y. and Engel, S., Protein Hot Spots: The Islands of Stability, *J. Mol. Biol.*, 415, 419–428, 2012.

- Kvasniča, F., Bíba, B., Ševčík, R., Voldřich, M. and Krátká, J., Analysis of the active components of silymarin, *J. Chromatogr. A*, 990, 239–245, 2003.
- Larson, A.J., Symons, J.D. and Jalili, T., Quercetin: a treatment for hypertension?—A review of efficacy and mechanisms, *Pharmaceuticals*, 3, 237–250, 2010.
- Leach, A.R., *Molecular modelling: Principles and Applications*, Prentice Hall, second edition, 662–663, 2001.
- Lee, K., Jeong, K., Lee, Y., Song, J.Y., Kim, M.S., Lee, G.S. and Kim, Y., Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase Inhibitors, *Eu. J. Med. Chem.* 45, 5420-5427, 2010.
- Lengauer, T. and Rarey, M., Computational methods for biomolecular docking, *Curr. Opin. Struct. Biol.*, 6, 402–406, 1996.
- Leonard, K.A., Gushue, J.M., Parks, D.J., Calvo, R.R., Milkiewicz, K.L., Marugán, J.J., Raboisson, P., Cummings, M.D., Grasberger, B.L., Johnson, D.L., Lu, T., Molloy, C.J. and Maroney, A.C., Benzodiazepinedione inhibitors of the Hdm2: p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo, *Mol. Cancer. Therap.*, 5, 160–169, 2006.
- Levine, A.J., P53, the cellular gatekeeper for growth and division, *Cell*, 88, 323–331, 1997.
- Lin, B., Kolluri, S.K., Lin, F., Liu, W., Han, Y.H., Cao, X., Dawson, M.I., Reed, J.C. and Zhang, X.K., Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3, *Cell*, 116, 527–540, 2004.

- Lindah, E., Hess, B., Van der Spoel, D., Gromacs 3.0: A package for molecular simulation and trajectory analysis, *J. Mol. Model.*, 7, 306-317, 2001.
- Liu, X., Dai, S., Zhu, Y., Marrack, P. and Kappler, J.W., The structure of a Bcl-xL/Bim fragment complex: implications for Bim function, *Immunity*, 19, 341-352, 2003.
- Liu, Y. and Gray, N.S., Rational design of inhibitors that bind to inactive kinase conformations, *Nat. Chem. Biol.*, 2: 358–364, 2006.
- Los M., Roodhart J.M., Voest E.E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. *Oncolo.* 2007; 12: 443-450.
- MacKerell. A.D. Jr, Bashford, D., Bellott, M. et al., All-atom empirical potential for molecular modeling and dynamics studies of proteins, *J. Phys. Chem. B*, 102, 3586-3616, 1998.
- MacLean, M. and Picard, D., Cdc37 goes beyond Hsp90 and kinases, *Cell Stress Chaper.*, 8, 114–119, 2003.
- Markowitz, S., Wang, J., Meyeroff, L., Parsons, R., Sun, L., Lutter- baugh, J., Fan, R., Zborowska, E., Kinzler, K. and Vogelstein, B., et al. Inactivation of the type II TGF-b receptor in colon cancer cells with microsatellite instability, *Science*, 268, 1336–1338, 1995.
- McCammon, J.A., Gelin, B.R. and Karplus, M., Dynamics of folded proteins, *Nature*, 267, 585-590, 1980.
- Medema, R.H. and Bos, J.L., The role of p21-ras in receptor tyrosine kinase signaling, *Crit. Rev. Oncog.*, 4, 615–661, 1993.

- Mendoza, E.E. and Burd, R., Quercetin as a systemic chemopreventative agent: structural and functional mechanisms, *Mini-Rev. Med. Chem.*, 11, 1216–1221, 2011.
- Moll, U.M., and Petrenko, O., the MDM2-p53 Interaction, *Mol. Cancer Res.*, 1, 1001–1008, 2003.
- Morris, G.M., Goodsell, D.S., Halliday, R.S., Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function, *J. Comp. Chem.*, 19, 1639-1662, 1998.
- Morris, G.M., Huey, R., Lindstrom, W. et al., AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility, *J. Comput. Chem.*, 30, 2785–2791, 2009.
- Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, *J. Immunol. Met.*, 65, 55–63, 1983.
- Murakami, A., Ashida, H. and Terao, J., Multitargeted cancer prevention by quercetin, *Can. Let.*, 269, 315–325, 2008.
- Naasani, I., Oh-Hashi, F., Oh-Hara, T., Feng, W.Y., Johnston, J., Chan, K. and Tsuruo, T., Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. *Cancer Res.*, 63, 824–830, 2003.
- Neckers, L. and Ivy, S.P., Heat shock protein 90, *Curr. Opin. Onco.*, 15, 419–424, 2003.
- Nieman, D.C., Henson, D.A., Maxwell, K.R., Williams, A.S., McAnulty, S.R. and Jin, F., et al., Effects of quercetin and EGCG on mitochondrial biogenesis and immunity, *Med. Sci. Sports Exerc.*, 41, 1467–1475, 2009.

- Obermann, W.M., Sondermann, H., Russo, A.A., Pavletich, N.P. and Hartl, F.U., In vivo function of Hsp90 is dependent on ATP binding and hydrolysis, *J. Cell Biol.*, 143, 901–910, 1998.
- Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W. and Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53, *Nature*, 362, 857 –860, 1993.
- Olthof, M.R., Hollman, P.C., Vree, T.B. and Katan, M.B., Bioavailabilities of quercetin-3- glucoside and quercetin-40-glucoside do not differ in humans, *J. Nutr.*, 130, 1200–1203, 2000.
- Oostenbrink, C., Villa, A., Mark, A.E. and van Gunsteren, W.F., A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6, *J. Comput. Chem.*, 25, 1656-1676, 2004.
- Opferman, J.T. and Korsmeyer, S.J., Apoptosis in the development and maintenance of the immune system, *Nat. Immunol.*, 4, 410-415, 2003.
- Oshiro, C.M., Kuntz, I.D. and Dixon, J.S., Flexible ligand docking using a genetic algorithm, *J. Computer-Aided Mol. Des.*, 9, 113–130, 1995.
- Pearl, L.H., Hsp90 and Cdc37 – a chaperone cancer conspiracy, *Curr. Opin. Gene. Develop.*, 15, 55–61, 2005.
- Peet, G.W. and Li, J., IkappaB kinases alpha and beta show a random sequential kinetic mechanism and are inhibited by staurosporine and quercetin, *J. Biol. Chem.*, 274, 32655–32661, 1999.

- Petros, A.M., Nettlesheim, D.G., Wang, Y., Olejniczak, E.T., Meadows, R.P., Mack, J., Swift, K., Matayoshi, E.D., Zhang, H., Thompson, C.B. and Fesik, S.W., Rationale for Bcl-xL/Bad peptide complex formation from structure. mutagenesis, and biophysical studies, *Protein Sci.*, 9, 2528-2534, 2000.
- Petros, A.M., Medek, A., Nettlesheim, D.G., Kim, D.H., Yoon, H.S., Swift, K. Matayoshi, E.D., Oltersdorf, T. and Fesik, S.W., Solution structure of the antiapoptotic protein Bcl-2, *Proc. Natl. Acad. Sci. USA*, 98, 3012-3017, 2001.
- Petros, A.M., Olejniczak, E.T. and Fesik, S.W., Structural biology of the Bcl-2 family of proteins, *Biochim. Biophys. Acta Mol. Cell Res.*, 1644, 83–94, 2004.
- Phillips, J.C., Braun, R., Wang, W. et al., Scalable molecular dynamics with NAMD, *J. Comput. Chem.*, 26, 1781-1802, 2009.
- Picard, D., Heat-shock protein 90, a chaperone for folding and regulation, *Cell. Mol. Life Sci.*, 59, 1640–1648, 2002.
- Pintoa, M. and Perezb, J.J., Rubio-Martinez, J. Molecular dynamics study of peptide segments of the BH3 domain of the proapoptotic proteins Bak, Bax, Bid and Hrk bound to the Bcl-xL and Bcl-2 proteins, *J. Computer-Aided Mol. Des.*, 18, 13-22, 2004.
- Ponder, J.W. and Case, D.A., Force fields for protein simulations, *Adv. Prot. Chem.*, 66, 27-85, 2003.
- Popowicz, G.M., Czarna, A., Wolf, S., Wang, K., Wang, W., Döling, A. and Holak, T.A., Structure of low molecular weight inhibitors bound to MDMX and MDM2 reveal

- new approaches for p53–MDMX/MDM2 antagonist drug discovery, *Cell Cycle*, 9, 1104–1111, 2010.
- Powers, M.V. and Workman, P., Inhibitors of the heat shock response: biology and pharmacology, *FEBS Lett.*, 581, 3758–3769, 2007.
- Price, D.J. and Brooks, C.L., Modern protein force fields behave comparably in molecular dynamics simulations, *J. Comput. Chem.*, 23, 1045-1057, 2002.
- Priego, S., Feddi, F., Ferrer, P., Mena, S., Benlloch, M., Ortega, A., Carretero, J., Obrador, E., Asensi, M. and Estrela, J.M., Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism, *Mol. Can. Therap.*, 7, 3330–3342, 2008.
- Prodromou, C. and Pearl, L.H., Structure and functional relationships of Hsp90, *Cur. Can. Drug Tar.*, 3, 301–323, 2003.
- Radkiewicz, J.L. and Brooks, C.L., Protein dynamics in enzymatic catalysis: exploration of dihydrofolate reductase, *J. Am. Chem. Soc.*, 122, 225-231, 2000.
- Rangaraju, A., Rao, A.V., A REVIEW ON MOLECULAR DOCKING – Novel tool in drug design and analysis, *J. Harmo. Res. Pharm.*, 2, 215-221, 2013.
- Reed, J.C., Apoptosis-based therapies, *Nat. Rev.*, 1, 111-121, 2002.
- Reed, S.I., The selection of *S. cerevisiae* mutants defective in the start event of cell division, *Genetics*, 95, 561–577, 1980.

- Richter, K., Moser, S., Hagn, F., Friedrich, R., Hainzl, O., Heller, M., Schlee, S., Kessler, H., Reinstein, J. and Buchner, J., Intrinsic inhibition of the Hsp90 ATPase activity, *J. Biol. Chem.*, 281, 11301–11311, 2006.
- Roe, S.M., Ali, M.M., Meyer, P., Vaughan, C.K., Panaretou, B., Piper, P.W., Prodromou, C. and Pearl, L.H., The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50 (Cdc37), *Cell*, 116, 87–98, 2004.
- Rohdewald, P., A review of the French maritime pine bark extract (pycnogenol), a herbal medication with a diverse clinical pharmacology, *Int. J. Clin. Pharmacol. Ther.*, 40, 158–168, 2002.
- Russo, M., Spagnuolo, C., Tedesco, I., Bilotto, S. and Russo, G.L., The flavonoid quercetin in disease prevention and therapy: facts and fancies, *Biochem. Pharm.* 83, 6–15, 2012.
- Ryška, J., Docking study of matrix, metalloproteinase inhibitors, MASARYK UNIVERSITY, 2011.
- Salsbury, F.R. Jr, Molecular dynamics simulations of protein dynamics and their relevance to drug discovery, *Cur. Opin. Pharm.*, 10, 738–744, 2010.
- Salsbury, F.R., Crowder, M.W., Kingsmore, S.F. and Huntley, J.J.A., Molecular dynamic simulations of the metallo-beta-lactamase from *Bacteroides fragilis* in the presence and absence of a tight-binding inhibitor, *J. Mol. Model.*, 15, 133-145, 2009.
- Salsbury, F.R., Crowley, M.F. and Brooks, C.L., Modeling of the metallo-beta-lactamase from *B-fragilis*: structural and dynamic effects of inhibitor binding, *Proteins*, 44, 448-459, 2001.

- Samuel, S., Tumilasci, V.F. and Oliere, S. et al., VSV oncolysis in combination with the Bcl-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia, *Mol. ther.*, 12, 2094-2103, 2010.
- Sarno, S., de Moliner, E., Ruzzene, M., Pagano, M.A., Battistutta, R. and Bain, J., et al., Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA), *Biochem. J.*, 374, 639–646, 2003.
- Sattler, M., Liang, H., Nettessheim, D., Meadows, R.P., Harlan, J.E., Eberstadt, M., Yoon, H.S., Shuker, S.B., Chang, B.S., Minn, A.J., Thompson, C.B. and Fesik, S.W., Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis, *Science*, 275, 983-986, 1997.
- Schlick, T., *Molecular Modeling and Simulation: An Interdisciplinary Guide*, Springer, 2010.
- Schmidt, U., Ahmed, J., Michalsky, E., Hoepfner, M. and Preissner, R., Comparative VEGF receptor tyrosine kinase modeling for the development of highly specific inhibitors of tumor angiogenesis, *Genome Inform.*, 20, 243-251, 2008.
- Schuttelkopf, A.W., van Aalten, D.M.F., PRODRG: A tool for high-throughput crystallography of protein-ligand complexes, *Acta Crystallogr.*, 60, 1355–1363, 2004.
- Scott, K.A., Bond, P.J., Ivetac, A., Chetwynd, A.P., Khalid, S. and Sansom, M.S.P., Coarsegrained MD simulations of membrane protein-bilayer self-assembly, *Structure*, 16, 621–630, 2008.

- Shalaby, F., Rossant, J., Yamaguchi, T.P., Gertsenstein, M., Wu, X.F., Brechtman, M.L. and Schuh, A.C., Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice, *Nat.*, 376, 62-66, 1995.
- Shangary, S. and Wang, S.M., Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy, *Annu. Rev. Pharmacol. Toxicol.*, 49, 223-241, 2009.
- Shangary, S. and Wang, S.M., Targeting the MDM2-p53 interaction for cancer therapy, Shao, J., Irwin, A., Hartson, S.D. and Matts, R.L., Functional dissection of Cdc37: characterization of domain structure and amino acid residues critical for protein kinase binding, *Biochem.*, 42, 12577-12588, 2003.
- Shao, J.Y., Irwin, A., Hartson, S.D. and Malts, R.L., Functional dissection of Cdc37: characterization of domain structure and amino acid residues critical for protein kinase binding, *Biochem.*, 42, 12577-12588, 2003.
- Shaw, D.E., Dror, R.O., Salmon, J.K. et al., Millisecond-scale molecular dynamics simulations on Anton, *Proceedings of the Conference on High Performance Computing, Networking, Storage and Analysis (SC09)*, ACM, New York, 2009.
- Shawver, L.K., Lipson, K.E., Fong, T.A.T., McMahon, G., Plowman, G.D. and Strawn, L.M., Receptor Tyrosine Kinases as Targets for Inhibition of Angiogenesis, *Drug Discov. Tod.*, 2, 50-63, 1997.
- Shiau, A.K., Harris, S.F., Southworth, D.R. and Agard, D.A., Structural analysis of E-coli hsp90 reveals dramatic nucleotide-dependent conformational rearrangements, *Cell* 127, 329-340, 2006.

- Silverstein, A.M., Grammatikakis, N., Cochran, B.H., Chinkers, M. and Pratt, W.B., P50 (Cdc37) binds directly to the catalytic domain of Raf as well as to a site on hsp90 that is topologically adjacent to the tetratricopeptide repeat binding site, *J. Biol. Chem.*, 273, 20090–20095, 1998.
- Singh, R.K., Gutman, M., Bucana, C.D., Sanchez, R., Llansa, N. and Fidler, I.J., Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas, *Proc. Natl. Acad. Sci. USA*, 92, 4562–4566, 1995.
- Slimestad, R., Fossen, T. and Vagen, I.M., Onions: a source of unique dietary flavonoids, *J. Agric. Food Chem.*, 55, 10067–10080, 2007.
- Smith, J.R., Clarke, P.A., de Billy, E. and Workman, P., Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors, *Oncogene*, 28, 157–169, 2009.
- Sreeramulu, S., Jonker, H.R., Langer, T., Richter, C., Lancaster, C.R. and Schwalbe, H., The human Cdc37.hsp90 complex studied by heteronuclear NMR spectroscopy, *J. Biol. Chem.*, 284, 3885–3896, 2009.
- Stebbins, C.E., Russo, A.A., Schneider, C., Rosen, N., Hartl, F.U. and Pavletich, N.P., Crystal structure of Hsp90–geldanamycin complex: targeting of a protein chaperone by an antitumor agent, *Cell*, 89, 239–250, 1997.
- Stetler-Stevenson, W.G., Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention, *J. Clin. Invest.*, 103, 1237–1241, 1999.
- Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Muhlhahn, P., Schumacher, R., Hesse, F., Kaluza, B.,

- Voelter, W., Engh, R.A. and Holak, T.A., Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53, *Biochem.*, 40, 336–344, 2001.
- Sudhamalla, B., Gokara, M., Ahalawat, N., Amooru, D.G., Subramanyam, R., Molecular dynamics simulation and binding studies of beta-sitosterol with human serum albumin and its biological relevance, *J. Phys. Chem.*, 114, 9054–9062, 2010.
- Suzuki, M., Youle, R.J. and Tjandra, N., Structure of Bax: coregulation of dimer formation and intracellular localization, *Cell*, 103, 645–654, 2000.
- Swanson, J.M.J., Henchman, R.H., McCammon, J.A., *Biophys. J.* 86, 67–74, 2004.
- Tang, G., Nikolovska-Coleska, Z., Qiu, S., Yang, C., Guo, J. and Wang, S., Acylpyrogallols as Inhibitors of Antiapoptotic Bcl-2 Proteins, *J. Med. Chem.*, 51, 717-720, 2008.
- Terasawa, K. and Minami, Y., A client-binding site of Cdc37, *FEBS J.*, 272, 4684–4690, 2005.
- Terasawa, K., Minami, M. and Constantly, Y., Updated knowledge of Hsp90, *J. Biochem.*, 137, 443–447, 2005.
- Terasawa, K., Yoshimatsu, K., Iemura, S., Natsume, T., Tanaka, K. and Minami, Y., Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases, *Mol. Cell. Biol.*, 26, 3378–3389, 2006.
- Thanyada, R., Nadtanet, N., Maturros, M., Nopporn, K., Pathumwadee, Y., Arthitaya, M., Supot, H., *J. Mol. Graph. Model.*, 29, 347–353, 2010.

- Traxler, P., Tyrosine kinases as targets in cancer therapy - successes and failures, *Exp. Opin. Ther. Targ.*, 7, 215-234, 2003.
- Traxler., P. and Furet, P., Strategies toward the design of novel and selective protein tyrosine kinase inhibitors, *Pharmacol. Ther.*, 82, 195–206, 1999.
- Trepel, J., Mollapour, M., Giaccone, G. and Neckers, L., Targeting the dynamic HSP90 complex in cancer, *Nat. Rev. Can.*, 10, 537–549, 2010.
- Uhrinova, S., Uhrin, D., Powers, H., Watt, K., Zheleva, D., Fischer, P., McInnes, C. and Barlow, P.N., Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. *J. Mol. Biol.*, 350, 587–598, 2005.
- Underiner, T.L., Ruggeri, B. and Gingrich, D.E., Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy, *Curr. Med. Chem.*, 11, 731-745, 2004.
- Van Gunsteren, W.F, Daura, X., Mark, A.E., The GROMOS force field. In *Encyclopedia of Computational Chemistry*; Von Rague Schleyer, P., Ed.; Wiley and Sons: Chichester, U.K., 2, 1211-1216, 1998.
- Van Gunsteren, W.F., Billeter, S.R., Eising, A.A. et al., *Biomolecular Simulation: The GROMOS96 Manual and User Guide*; Vdf Hochschulverlag AG: Zurich, 1996.
- Vasilyeva, A., Clodfelter, J.E., Rector, B., Hollis, T., Scarpinato, K.D. and Salsbury, F.R., Small molecule induction of MSH2-dependent cell death suggests a vital role of mismatch repair proteins in cell death. *DNA Rep.*, 8, 103-113, 2009.

- Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N. and Liu, E.A., In vivo activation of the p53 pathway by small-molecule antagonists of MDM2, *Science*, 303, 844–848, 2004.
- Vaughan, C.K., Gohlke, U., Sobott, F., Good, V.M., Ali, M.M.U., Prodromou, C., Robinson, C.V., Saibil, H.R. and L.H. Pearl, Structure of an Hsp90–Cdc37–Cdk4 complex, *Mol. Cell*, 23, 697–707, 2006.
- Vaziri, H. and Benchimol, S., Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span, *Curr. Biol.*, 8, 279–282, 1998.
- Vaziri, H., Benchimol, S., Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span, *Curr. Biol.*, 8, 279–282, 1998.
- Veikkola, T. and Alitalo, K., VEGFs, receptors and angiogenesis, *Semin. Cancer Biol.*, 9, 211–220, 1999.
- Vidya Priyadarsini, R., Senthil Murugan, R., Maitreyi, S., Ramalingam, K., Karunagaran, D. and Nagini, S., The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF- κ B inhibition, *Euro. J. Pharma.*, 649, 84–91, 2010.
- Vilenchik, M., Solit, D., Basso, A., Huezo, H., Lucas, B., He, H., Rosen, N., Spampinato, C., Modrich, P. and Chiosis, G., Targeting wide-range oncogenic transformation via PU24FCL, a specific inhibitor of tumor Hsp90, *Chem. Biol.* 11, 787–797, 2004.

- Voelz, V.A., Bowman, G.R., Beauchamp, K., Pande, V.S., Molecular simulation of ab initio protein folding for a millisecond folder NTL9 (1–39), *J. Am. Chem. Soc.*, 132, 1526–1528, 2010.
- Vogelstein, B., Lane, D. and Levine, A.J., The p53 tumour-suppressor gene integrates numerous signals that control cell life and death, as when a highly connected node in the Internet breaks down, the disruption of p53 has severe consequences, *Nature*, 408, 307–310, 2000.
- Volpert, O.V., Dameron, K.M. and Bouck, N., Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity, *Oncogene*, 14, 1495–1502, 1997.
- Vorontsov Ivan, I., Miyashita, O., *J. Comput. Chem.* 32, 1043–1053 2011.
- Wallace, S.N., Carrier, D.J. and Clausen, E.C., Batch solvent extraction of flavonolignans from milk thistle (*Silybum marianum* L. Gaertner), *Phytochem. Anal.*, 16, 7–16, 2005.
- Wang, K., Gross, A., Waksman, G. and Korsmeyer, S.J., Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing, *Mol. Cell Biol.*, 18, 6083–6089, 1998.
- Wayne, N. and Bolon, D.N., Dimerization of Hsp90 is required for in vivo function, design and analysis of monomers and dimers, *J. Biol. Chem.*, 282, 35386–35395, 2007.
- Wegele, H., Müller, L. and Buchner, J., Hsp70 and Hsp90—a relay team for protein folding, *Rev. Physiol. Biochem. Pharm.*, 151, 1–44, 2004.

- Weidmann, A.E., Dihydroquercetin: More than just an impurity?, *Eur. J. Pharm.*, 684, 19–26, 2012.
- Weinberg, R.A., The retinoblastoma protein and cell cycle control, *Cell*, 81, 323–330, 1995.
- Weinmann, S., Roll, S., Schwarzbach, C., Vauth, C. and Willich, S.N., Effectsof Ginkgo biloba in dementia:systematicreviewandmeta-analysis, *BMC Geriatry*, 17,10–14, 2010.
- Welch, W.J. and Feramisco, J.R., Purification of the major mammalian heat-shock proteins, *J. Biol. Chem.*, 257, 4949–4959, 1982.
- Werb, Z., ECM and cell surface proteolysis: regulating cellular ecology, *Cell*, 91, 439–442, 1997.
- Werner, T., Morris, M.B., Dastmalchi, S. and Church, W.B., Structural modelling and dynamics of proteins for insights into drug interactions, *Adv. Drug Del. Rev.*, 64, 323–343, 2012.
- Whitesell, L. and Lindquist, S.L., HSP90 and the chaperoning of cancer, *Nat. Rev. Can.*, 5, 761–772, 2005.
- Willis, S.N., Fletcher, J.I., Kaufmann, T., Van Delft, M.F., Chen, L., Czabotar, P.E., Ierino, H., Lee, E.F., Fairlie, W.D., Bouillet, P., Strasser, A., Kluck, R.M., Adams, J.M., Huang, D.C.S., Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak, *Science*, 315, 856-859, 2007.
- Workman, P., Overview: translating Hsp90 biology into Hsp90 drugs, *Curr. Can. Drug Tar.*, 3, 297–300, 2003.

- Xie, X., Yin, J., Jia, Q., Wang, J., Zou, C., Brewer, K.J., Colombo, C., Wang, Y., Huang, G. and Shen, J., Quercetin induces apoptosis in the methotrexate-resistant osteosarcoma cell line U2-OS/MTX300 via mitochondrial dysfunction and dephosphorylation of Akt, *Onco. Rep.*, 26, 687–693, 2010.
- Yang, C.S., Landau, J.M., Huang, M.T. and Newmark, H.L., Inhibition of carcinogenesis by dietary polyphenolic compounds, *Ann. Rev. Nut.* 21, 381–406, 2001.
- Yang, E.Y., Lee, T.A. and Oliner, J.D., Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2–Tumor Protein 53 Protein–Protein Interaction, *J. Med. Chem.*, 52 , 7044–7053, 2009.
- Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Steinberg, S.M., Chen, H.X. and Rosenberg, S.A., A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, *N. Engl. J. Med.*, 349, 427-434, 2003.
- Yang, Y., Shi, L., Zhou, Y., Li, H., Zhu, Z. and Zhu, H., Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors, *Bioorg. Med. Chem. Lett.*, 20, 6653–6656, 2010.
- Yanga, W., Gongb, X., Zhaoc, X., Anb, W., Wang, X., Wang, M., Capsaicin Induces Apoptosis in HeLa Cells via Bax/Bcl-2 and Caspase-3 Pathways, *Asian J. Trad. Med.*, 1, 3-4, 2006.

- Yao, Y., Harrison, C.B., Freddolino, P.L., Schulten, K., Mayer, M.L., Molecular mechanisms of ligand recognition by NR3 subtype glutamate receptors, *EMBO J.*, 27, 2158-2170, 2008.
- Yin, X.M., Oltvai, Z.N. and Korsmeyer, S.J., BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax, *Nature*, 369, 321–323, 1994.
- Zha, H., Aime'-Sempe', C., Sato, T. and Reed, J.C., Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2, *J. Biol. Chem.*, 271, 7440–7444, 1996.
- Zhang, J., Li, W.F., Wang, J., Qin, M., Wu, L., Yan, Z.Q., Xu, W.X., Zuo, G.H. and Wang, W., Protein folding simulations: from coarse-grained Model to all-atom model, *IUBMB Life*, 61, 627-643, 2009.
- Zhang, T., Hamza, A., Cao, X., Wang, B., Yu, S., Zhan, C.G. and Sun, D., A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells, *Mol. Can. Therap.*, 7, 162–170, 2008.
- Zhang, T., Li, Y., Yu, Y., Zou, P., Jiang, Y. and Sun, D., Characterization of celastrol to inhibit Hsp90 and Cdc37 interaction, *J. Biol. Chem.*, 284, 35381–35399, 2009.
- Zhang, W., Hirshberg, M., McLaughlin, S.H., Lazar, G.A., Grossmann, J.G., Nielsen, P.R., Sobott, F., Robinson, C.V., Jackson, S.E. and Laue, E.D., Biochemical and structural studies of the interaction of Cdc37 with Hsp90, *J. Mol. Biol.*, 340, 891–907, 2004.

- Zhao, J., Wang, M., Chen, J., Luo, A., Wang, X., Wu, M., Yin, D. and Liu, Z., The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53–HDM2 complex structure, *Cancer. Lett.*, 183, 69–77, 2002.
- Zhao, Q., Boschelli, F., Caplan, A.J. and Arndt, K.T., Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4, *J. Biol. Chem.*, 279, 12560–12564, 2004.
- Zhou, H., Chen, J., Meagher, J.L., Yang, C., Aguilar, A. Liu, L., Bai, L., Cong, X., Cai, Q., Fang, X., Stuckey, J.A. and Wang, S. Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold, *J. Med. Chem.*, 55, 4664-4682, 2012.